Clarivate Launches DRG Fusion - A New Life Sciences Analytics Product Powered by Real-World Data
Clarivate (NYSE:CLVT) has launched DRG Fusion, a new analytics platform designed to support commercial analytics in life sciences. The platform integrates real-world data from medical and pharmacy claims to help biopharma and medtech organizations optimize their commercial strategies.
The platform features modular data analytics products with configurable dashboards supporting patient journey analysis, commercial targeting, market access optimization, and patient segmentation. Fusion streamlines data management by providing ready-made visuals and tables to accelerate commercial decisions.
The company plans to introduce AI-driven and self-service features to Fusion in 2025, demonstrating its commitment to delivering user-centric solutions for healthcare challenges.
Clarivate (NYSE:CLVT) ha lanciato DRG Fusion, una nuova piattaforma di analisi progettata per supportare l'analisi commerciale nelle scienze della vita. La piattaforma integra dati reali provenienti da richieste mediche e farmaceutiche per aiutare le organizzazioni biopharma e medtech a ottimizzare le proprie strategie commerciali.
La piattaforma offre prodotti di analisi dei dati modulari con dashboard configurabili che supportano l'analisi del percorso del paziente, il targeting commerciale, l'ottimizzazione dell'accesso al mercato e la segmentazione dei pazienti. Fusion semplifica la gestione dei dati fornendo visualizzazioni e tabelle pronte all'uso per accelerare le decisioni commerciali.
L'azienda prevede di introdurre funzionalità basate su AI e self-service in Fusion nel 2025, dimostrando il suo impegno a fornire soluzioni centrate sull'utente per le sfide sanitarie.
Clarivate (NYSE:CLVT) ha lanzado DRG Fusion, una nueva plataforma de análisis diseñada para apoyar el análisis comercial en las ciencias de la vida. La plataforma integra datos del mundo real provenientes de reclamaciones médicas y farmacéuticas para ayudar a las organizaciones biopharma y medtech a optimizar sus estrategias comerciales.
La plataforma cuenta con productos de análisis de datos modulares con paneles configurables que respaldan el análisis del recorrido del paciente, el direccionamiento comercial, la optimización del acceso al mercado y la segmentación de pacientes. Fusion simplifica la gestión de datos al proporcionar visuales y tablas predefinidas para acelerar las decisiones comerciales.
La empresa planea introducir características impulsadas por IA y de autoservicio en Fusion en 2025, demostrando su compromiso de ofrecer soluciones centradas en el usuario para los desafíos de la salud.
Clarivate (NYSE:CLVT)는 생명과학 분야의 상업 분석을 지원하기 위해 설계된 새로운 분석 플랫폼인 DRG Fusion을 출시했습니다. 이 플랫폼은 의학 및 약국 청구에서 실시간 데이터를 통합하여 생명공학 및 의료기술 조직이 상업 전략을 최적화하는 데 도움을 줍니다.
플랫폼은 환자 여정 분석, 상업적 타겟팅, 시장 접근 최적화 및 환자 세분화를 지원하는 구성 가능한 대시보드를 갖춘 모듈형 데이터 분석 제품을 제공합니다. Fusion은 상업적 결정을 가속화하기 위해 즉시 사용할 수 있는 시각 자료와 표를 제공하여 데이터 관리를 간소화합니다.
회사는 2025년에 Fusion에 AI 기반의 자가 서비스 기능을 도입할 계획이며, 이는 의료 과제에 대한 사용자 중심 솔루션을 제공하기 위한 다짐을 나타냅니다.
Clarivate (NYSE:CLVT) a lancé DRG Fusion, une nouvelle plateforme d'analyse conçue pour soutenir l'analyse commerciale dans les sciences de la vie. La plateforme intègre des données du monde réel provenant de réclamations médicales et pharmaceutiques pour aider les organisations biopharma et medtech à optimiser leurs stratégies commerciales.
Cette plateforme propose des produits d'analyse de données modulaires avec des tableaux de bord configurables, soutenant l'analyse du parcours des patients, le ciblage commercial, l'optimisation de l'accès au marché et la segmentation des patients. Fusion simplifie la gestion des données en fournissant des visualisations et des tableaux prêts à l'emploi pour accélérer les décisions commerciales.
L'entreprise prévoit d'introduire des fonctionnalités basées sur l'IA et en libre-service dans Fusion en 2025, démontrant ainsi son engagement à fournir des solutions axées sur l'utilisateur pour relever les défis de la santé.
Clarivate (NYSE:CLVT) hat DRG Fusion eingeführt, eine neue Analyseplattform, die darauf abzielt, kommerzielle Analysen im Bereich der Lebenswissenschaften zu unterstützen. Die Plattform integriert reale Daten aus medizinischen und pharmazeutischen Abrechnungen, um Biopharma- und Medizintechnikorganisationen bei der Optimierung ihrer kommerziellen Strategien zu helfen.
Die Plattform bietet modulare Datenanalyseprodukte mit konfigurierbaren Dashboards, die die Analyse von Patientenreisen, kommerzielle Zielsetzungen, Marktzugangsoptimierung und Patientensegmentierung unterstützen. Fusion vereinfacht das Datenmanagement, indem sie sofort einsatzbereite Visualisierungen und Tabellen bereitstellt, um kommerzielle Entscheidungen zu beschleunigen.
Das Unternehmen plant, 2025 KI-gesteuerte und Self-Service-Funktionen in Fusion einzuführen, was sein Engagement zeigt, benutzerzentrierte Lösungen für Gesundheitsherausforderungen anzubieten.
- Launch of new analytics platform expanding product portfolio
- Platform addresses growing market need for integrated healthcare data analytics
- Planned AI-driven features expansion in 2025 showing innovation pipeline
- None.
Insights
The launch of DRG Fusion represents a strategic move by Clarivate to strengthen its position in the life sciences analytics market. The platform addresses a critical gap in the healthcare data analytics space by simplifying complex data management for biopharma and medtech companies. While this product launch is noteworthy, its immediate financial impact may be as enterprise software typically has extended sales cycles and gradual revenue recognition.
The platform's modular approach, focusing on commercial targeting, patient journey analysis and market access optimization, aligns with current industry trends toward data-driven decision-making in healthcare. The planned AI-driven features for 2025 suggest a forward-looking product roadmap, though competitive pressures from established players like IQVIA and Veeva Systems could impact market penetration.
For investors, this represents incremental progress in Clarivate's strategy to expand its life sciences offerings, but may take several quarters to materially impact revenue. The real value proposition lies in the potential for recurring revenue through subscription-based pricing models typical in enterprise software.
DRG Fusion's technical architecture leverages integrated real-world data to create a competitive advantage in the healthcare analytics space. The platform's focus on pre-built modules and configurable dashboards indicates a user-centric design approach that could accelerate adoption among commercial teams who typically struggle with complex data analysis tools.
The platform's ability to integrate medical and pharmacy claims data provides a comprehensive view of patient journeys - a valuable capability for pharmaceutical companies looking to optimize their market strategies. However, success will largely depend on data quality, integration capabilities and the effectiveness of the upcoming AI features in delivering actionable insights.
While innovative, the platform enters a mature market with established players. The key differentiator will be Clarivate's ability to demonstrate superior data integration and insights generation compared to existing solutions. Early market reception and customer adoption rates will be important indicators of long-term success.
New modular analytics solution empowers commercial teams to optimize strategies and improve patient outcomes
Biopharma and medtech organizations face increasing challenges in extracting insights from fragmented data sources while adapting to competitive pressures and shifting market demands. Fusion addresses these issues by delivering market data and analytics from integrated medical and pharmacy claims and other real-world data sources, empowering life science organizations to create a healthier tomorrow. Its user-tested workflows and on-going data refreshes empower teams to quickly identify gaps in product positioning and uncover opportunities to enhance patient acquisition and retention.
Fusion addresses the critical needs of biopharma and medtech commercial, sales and marketing teams by offering modular data analytics products aligned to functional team needs. Pre-built modules provide users with configurable dashboards to support patient journey analysis, commercial targeting, market access optimization and patient segmentation.
Abeezer Tapia, Senior Vice President & General Manager, Real-World Data, Life Sciences & Healthcare, Clarivate, said: "Fusion is built to harness real-world data in specific ways to help our customers maximize their product value. Its four product workflows cater to specific objectives—be it sizing and segmenting target patient populations, identifying and mitigating leakage points across the patient journey, deploying sales teams based on precise commercial targeting, or designing value messages and assistance programs to optimize access. With data mastered at the drug and device level, Fusion provides the targeted market insights that are critical to inform biopharma and medtech decision-making."
Henry Levy, President, Life Sciences & Healthcare, Clarivate, added: "Fusion demonstrates the robustness of life sciences data from Clarivate and its wide-ranging commercial applications. Its scalable data architecture is carefully designed to rapidly deliver insights across patient diseases and sub-population cohorts. We are committed to investing in innovative technologies that empower our clients to address healthcare's most pressing challenges. With new AI-driven and self-service features set to launch in Fusion in 2025, we remain focused on delivering user-centric solutions that drive meaningful value and impact for our customers."
Fusion streamlines the data management and querying process for life sciences organizations by simplifying complex data analysis with ready-made, informative visuals and tables accelerating commercial decisions.
To learn more about how this modular analytics platform can help organizations optimize their product launch and growth strategies while improving patient outcomes, visit here.
About Clarivate Real-World Data
Clarivate offers a unique blend of products and expert consultancy to support you at every stage of your journey with real-world data (RWD). Our platform seamlessly integrates medical and pharmacy claims, SDoH, mortality and registry data to deliver valuable insights across the development lifecycle. With cohort-specific data tailored to your needs, we provide precise answers to key business questions. Our modular analytics platform, designed by data scientists, epidemiologists, and former clinicians, provides functional insights to enhance your commercial strategy. We also offer expert support in data configuration, advanced ML models, and the integration of disparate datasets to ensure you have the tools and expertise to drive success. Offerings include Clarivate Real-World Data Nucleus, Clarivate Real-World Data Fusion Platform, Clarivate Real-World Data Consulting & Insights and Clarivate Real-World Data Rare Disease Franchise.
About Clarivate
Clarivate™ is a leading global provider of transformative intelligence. We offer enriched data, insights & analytics, workflow solutions and expert services in the areas of Academia & Government, Intellectual Property and Life Sciences & Healthcare. For more information, please visit www.Clarivate.com.
Media Contact:
Catherine Daniel
Director, External Communications, Life Sciences & Healthcare
newsroom@Clarivate.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/clarivate-launches-drg-fusion---a-new-life-sciences-analytics-product-powered-by-real-world-data-302349862.html
SOURCE Clarivate Plc
FAQ
What is DRG Fusion and when did Clarivate (CLVT) launch it?
What are the main features of Clarivate's DRG Fusion platform?
What new features will be added to Clarivate's DRG Fusion in 2025?
How does DRG Fusion benefit biopharma and medtech organizations?
